DK1202746T3 - NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer - Google Patents

NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer

Info

Publication number
DK1202746T3
DK1202746T3 DK00950930T DK00950930T DK1202746T3 DK 1202746 T3 DK1202746 T3 DK 1202746T3 DK 00950930 T DK00950930 T DK 00950930T DK 00950930 T DK00950930 T DK 00950930T DK 1202746 T3 DK1202746 T3 DK 1202746T3
Authority
DK
Denmark
Prior art keywords
nsaid
inhibition
treatment
colorectal cancer
kinase inhibitor
Prior art date
Application number
DK00950930T
Other languages
Danish (da)
English (en)
Inventor
Philip Frost
Carolyn Mary Discafani-Marro
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1202746T3 publication Critical patent/DK1202746T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00950930T 1999-08-12 2000-08-02 NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer DK1202746T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12

Publications (1)

Publication Number Publication Date
DK1202746T3 true DK1202746T3 (da) 2007-01-02

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00950930T DK1202746T3 (da) 1999-08-12 2000-08-02 NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer

Country Status (24)

Country Link
EP (1) EP1202746B1 (ja)
JP (1) JP2003507342A (ja)
KR (1) KR20020018201A (ja)
CN (1) CN1229142C (ja)
AR (1) AR029763A1 (ja)
AT (1) ATE341341T1 (ja)
AU (1) AU783116B2 (ja)
BR (1) BR0013219A (ja)
CA (1) CA2380904C (ja)
CZ (1) CZ2002474A3 (ja)
DE (1) DE60031127T2 (ja)
DK (1) DK1202746T3 (ja)
EA (1) EA006876B1 (ja)
ES (1) ES2272305T3 (ja)
HK (1) HK1042244A1 (ja)
HU (1) HUP0203162A3 (ja)
IL (1) IL147913A0 (ja)
MX (1) MXPA02001448A (ja)
NO (1) NO20020663L (ja)
NZ (1) NZ517120A (ja)
PL (1) PL353267A1 (ja)
PT (1) PT1202746E (ja)
WO (1) WO2001012227A1 (ja)
ZA (1) ZA200201156B (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
BR0109165A (pt) * 2000-03-13 2003-04-22 American Cyanamid Co Método de tratamento de pólipos colÈnicos
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
WO2003000705A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
JP4326328B2 (ja) 2001-07-16 2009-09-02 アストラゼネカ アクチボラグ キノリン誘導体及びそれらのチロシンキナーゼ阻害薬としての使用
BR0213486A (pt) * 2001-10-25 2005-05-10 Novartis Ag Combinações que compreendem um inibidor seletivo de ciclooxigenase-2
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
AU2003250701A1 (en) 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
CA2542007C (en) 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
UA85706C2 (en) 2004-05-06 2009-02-25 Уорнер-Ламберт Компани Ллси 4-phenylaminoquinazolin-6-yl amides
AU2005249206A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an EGFR-inhibitor
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2118075A1 (de) 2007-02-06 2009-11-18 Boehringer Ingelheim International GmbH Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP2225226B1 (en) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
JP5336516B2 (ja) 2008-02-07 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
ES2444128T3 (es) 2008-05-13 2014-02-24 Astrazeneca Ab Nueva SAL-554
JP2011520970A (ja) 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
CA2999321A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
PL387312A1 (pl) * 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
CA2752826A1 (en) 2009-04-20 2010-10-28 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
RU2606114C2 (ru) * 2011-06-01 2017-01-10 Джейнус Байотерапьютикс, Инк. Новые модуляторы иммунной системы

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391872B1 (en) * 1997-11-04 2002-05-21 Pfizer Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
CN1278176A (zh) * 1997-11-06 2000-12-27 美国氰胺公司 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用

Also Published As

Publication number Publication date
ATE341341T1 (de) 2006-10-15
MXPA02001448A (es) 2002-07-02
WO2001012227A1 (en) 2001-02-22
JP2003507342A (ja) 2003-02-25
DE60031127T2 (de) 2007-02-01
HUP0203162A2 (hu) 2003-01-28
KR20020018201A (ko) 2002-03-07
EA006876B1 (ru) 2006-04-28
CA2380904C (en) 2009-02-10
BR0013219A (pt) 2002-04-23
NO20020663L (no) 2002-04-09
ZA200201156B (en) 2003-05-12
IL147913A0 (en) 2002-08-14
DE60031127D1 (de) 2006-11-16
HUP0203162A3 (en) 2006-07-28
PT1202746E (pt) 2007-01-31
CZ2002474A3 (cs) 2003-02-12
HK1042244A1 (zh) 2002-08-09
AU783116B2 (en) 2005-09-29
CA2380904A1 (en) 2001-02-22
CN1370080A (zh) 2002-09-18
AR029763A1 (es) 2003-07-16
EP1202746B1 (en) 2006-10-04
NO20020663D0 (no) 2002-02-11
ES2272305T3 (es) 2007-05-01
NZ517120A (en) 2004-10-29
AU6395900A (en) 2001-03-13
PL353267A1 (en) 2003-11-03
EP1202746A1 (en) 2002-05-08
CN1229142C (zh) 2005-11-30
EA200200246A1 (ru) 2002-08-29

Similar Documents

Publication Publication Date Title
DK1202746T3 (da) NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
NO20002166D0 (no) Anvendelse av quinazolinderivater som tyrosinkinaseinhibitorer for behandling av kolonpolypper
DK1263503T3 (da) Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypper
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1165078T3 (da) Fremgangsmåder til induktion af cancercelledöd og tumorregression
NO20021820L (no) Tyrosinkinaseinhibitorer
DK1576132T3 (da) Nukleinsyrer benævnt 273p4b7 og anvendelse heraf til detektering af cancer
NO20012583D0 (no) Quinoliner og quinoksalinforbindelser som PDGF-R- og/eller LCK-tyrosinkinase-inhibitorer
IS7233A (is) Kínasólín afleiður til meðhöndlunar á afbrigðilegum frumuvexti
ATE412070T1 (de) Prognose von kolorektalem krebs
NO20033635D0 (no) Pyrimidinderivater for inhibering av celle-formering
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
NO20015516L (no) Preparater og anvendelser av ET743 for behandling av kreft
DK1432417T3 (da) Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer
NO20022245D0 (no) Onkolyttiske kombinasjoner for behandling av cancer
NO20020358L (no) Anvendelse av etodolac til behandling av kreft
NO20034350D0 (no) Optisk avbilding av kolorektal kreft
AU2002311859A1 (en) Compositions and methods for treating colorectal polyps and cancer
DK1239862T3 (da) Farmaceutisk præparat indeholdende cytostatika og eletronacceptorer til behandling af kræft
DK1512758T3 (da) Prognose af colorektal cancer
DK1330442T3 (da) Phthalazinon-derivativer
DK1567524T3 (da) Thia-epothilonderivater til behandling af cancer
DK1140147T3 (da) hCG-terapi til behandling af metastatisk brystcancer